DexCom (NASDAQ:DXCM) shares plunged to the lowest level in more than four years on Friday after the medical device maker slashed its full-year revenue outlook along with its Q2 2024 financials, ...
DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...
In December, online rumors hinted at the fact that Dexcom may be planning to sunset its G6 CGM sensor model. The company has now started to notify patients of the discontinuation plan. The company ...
EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical ...
DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results